1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPrevention RFP (Alzheimer's Disease and Related Dementias) is sponsored by Alzheimer's Drug Discovery Foundation. The ADDF provides funding to academic centers and biotechs advancing therapeutic and biomarker development for Alzheimer's and related dementias. This program seeks proposals focused on prevention.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Alzheimer's Drug Discovery Foundation (ADDF) Grants | Science Internal Alzheimer's Drug Discovery Foundation (ADDF) Grants Alzheimer's Drug Discovery Foundation (ADDF) Grants Alzheimer's Drug Discovery Foundation (ADDF) Drug Development [Letter of Intent] The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias.
Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.
Up to $5,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment.
Neuroimaging and CSF Biomarker Program [Letter of Intent] The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
Specifically, this RFP focuses on: - Developing novel PET ligands for clinical trials - Supporting novel CSF biomarkers - Validating innovative MRI approaches in larger cohorts - Developing novel measures of functional activity such as EEG Up to $600,000 based on stage and scope of research.
Prevention Pipeline [Letter of Intent] The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
The Prevention RFP supports: - Studies of Cognitive Decline and Risk Reduction - Comparative Effectiveness Research - Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) - Up to $5,000,000 for clinical trials based on stage and scope of research - For studies requiring additional support, co-funding from other funding agencies or investors is encouraged - Payment structure will be negotiated and based on milestone achievements and recruitment Accelerating Drug Discovery for FTD [Letter of Intent] There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients.
Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies.
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP). $300,000-$350,000 based on stage and scope of research. Slightly higher budgets can be considered.
Please contact us for review and approval. https://www. alzdiscovery.
org/research-and-grants/funding-opportunities
According to the current listing, eligibility includes: Academic centers and biotechs from around the world are eligible. Confirm the full requirements in the official notice before applying.
The published deadline was September 14, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Prevention RFP (Alzheimer's Disease and Related Dementias) is funded by Alzheimer's Drug Discovery Foundation. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleDARPA's DIAL program already had AI rediscover the Kalman filter and wavelets from scratch. SPEED DIAL (DPA26TZ05-DV003) funds the unglamorous next step: turning algorithm discovery into a tool that plugs into MATLAB, Simulink, and COMSOL. Up to $750,000 base plus a $1.25 million option, Direct to Phase II only, with a three-accomplishment feasibility gate and a mandatory university partner. Here is the milestone schedule, the interpretability requirement, and who is actually eligible.
Read articleAs of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read article